NCT00002389View on ClinicalTrials.gov

The Safety and Effectiveness of Lamivudine Plus Zidovudine, Used With and Without 1592U89, in HIV-1 Infected Patients Who Have Never Taken Anti-HIV Drugs

PHASE3CompletedINTERVENTIONAL
Enrollment

210

Participants

Timeline

Start Date

Not specified

Conditions
HIV Infections
Interventions
DRUG

Abacavir sulfate

DRUG

Lamivudine

DRUG

Zidovudine

Trial Locations (15)

10011

St Vincent's Hosp and Med Ctr / AIDS Ctr, New York

10027

Harlem Hosp, New York

20007

Georgetown Univ Med Ctr, Washington D.C.

27710

Duke Univ Med Ctr / Dept of Medicine, Durham

33136

Univ of Miami Dept of Medicine, Miami

60612

Rush Med College / Rush Presbyterian - St Luke's Med Cen, Chicago

75225

Dr Nicholaos Bellos, Dallas

90036

Kraus Med Partners, Los Angeles

94705

East Bay AIDS Ctr, Berkeley

452670405

Univ of Cincinnati / Holmes Hosp, Cincinnati

770303498

Baylor College of Medicine / Dept of Medicine, Houston

021182393

Boston Med Ctr / Evans - 556, Boston

07102

Saint Michael's Med Ctr / Dept of Infectious Diseases, Newark

Unknown

Toronto Gen Hosp, Toronto

00907

San Juan AIDS Program, Santurce

Sponsors

Lead Sponsor

Glaxo Wellcome
All Listed Sponsors
lead

Glaxo Wellcome

INDUSTRY

NCT00002389 - The Safety and Effectiveness of Lamivudine Plus Zidovudine, Used With and Without 1592U89, in HIV-1 Infected Patients Who Have Never Taken Anti-HIV Drugs | Biotech Hunter | Biotech Hunter